Pardes poaches former Dermira CEO Thomas Wiggans amid rocky ride at stock marketnews2022-03-03T15:38:39+00:00March 3rd, 2022|FierceBiotech|
Pardes poaches former Dermira CEO Wiggans amid rocky ride at stock marketnews2022-03-03T15:38:39+00:00March 3rd, 2022|FierceBiotech|
Roche plans 4-year late-stage trial for Alzheimer’s candidate while awaiting crucial H2 readoutnews2022-03-03T14:14:05+00:00March 3rd, 2022|FierceBiotech|
Atlas lands $450M fund to build fresh batch of biotechsnews2022-03-03T13:46:56+00:00March 3rd, 2022|FierceBiotech|
AstraZeneca, Sanofi reveal mixed hand in high-stakes RSV game, with hospitalization miss tarnishing primary endpoint hitnews2022-03-03T13:01:37+00:00March 3rd, 2022|FierceBiotech|
As Russia stacked troops on Ukraine’s border, Karuna’s trial partners got readynews2022-03-03T06:10:18+00:00March 3rd, 2022|FierceBiotech|
Chutes & Ladders—Merck chief patient officer to retire to become CEO of NIH nonprofitnews2022-03-02T20:40:57+00:00March 2nd, 2022|FierceBiotech|
Avalo adjusts almost entire pipeline weeks after CEO, CFO say sayonaranews2022-03-02T19:45:35+00:00March 2nd, 2022|FierceBiotech|
Foresite Labs’ new $173M fund to bankroll fewer startups but ‘big ideas’ fueled by datanews2022-03-02T18:42:44+00:00March 2nd, 2022|FierceBiotech|
SAB’s shares drop 45% after NIH ditches COVID-19 trial due to waning hospitalizationsnews2022-03-02T15:11:06+00:00March 2nd, 2022|FierceBiotech|
